Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Understanding the Role of Uric Acid in Gout

Ruth Jessen Hickman, MD  |  Issue: September 2022  |  September 6, 2022

“This school believes that crystal deposition is the primary step in the development of gouty tophi and therefore attribute tissue necrosis to the damaging effect of the crystals,” he said. “In opposition are other authors … who defend the idea that the tissue necrosis of the gouty lesion is the primary event, and the deposition of uric acid salts is secondary to this.”5

In his own work injecting urate crystals into rabbits, Dr. Freudweiler observed evidence of acute inflammation and tissue necrosis in those injected.5 Some other early research

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

also found inflammatory reactions resulting from the injection of crystalline uric acids or other forms of urates into living tissue.5 But much of this work fell into obscurity, and Dr. Garrod’s work was left unconfirmed.

Intervening Years

In the following years, the medical community did come to accept a pathophysiologic role between tophaceous gout and hyperuricemia. Salicylates, the first uricosuric agents when given in high doses, and then later agents, such as probenecid, could successfully lower serum urate and gradually dissolve tophaceous gout deposits.2,3

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Through the 1950s, however, medical texts were noncommittal about the relationship between urates and the pathogenesis of acute inflammatory gouty attacks, and the mechanism of acute gouty arthritis was studied relatively little.2

It was well established by then that some, but not all, people with hyperuricemia suffered attacks of acute gouty arthritis. On the other hand, when solutions of non-crystallized sodium urate were injected into humans, this had not seemed to trigger a gout flare, nor did the administration of large doses of uric acid delivered intravenously.1 At the time, this was a primary point made by those arguing that urates played no role in triggering acute gouty flares.2

Modern Study of Gout

One might argue that the modern study of gout began in 1961, with work led by Daniel J. McCarty Jr., MD, then head of rheumatology at the University of Pennsylvania, Philadelphia.6,7 Using polarized light microscopy, McCarty et al. were able to show crystals of monosodium urate in gouty synovial fluid, often in the process of undergoing phagocytosis. These had been much more difficult to see via the standard light microscopy used previously.

Dr. McCarty

The next year, two key complementary papers in the Journal of the American Medical Association (JAMA) and The Lancet helped definitively establish the role of elevated serum urate and sodium urate crystals in triggering acute gout flares.1,2

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutGout Resource CenterLost & FoundUric acid

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Gout, Glucose Metabolism and Obesity: A Case Review

    November 2, 2014

    New research explores association between hyperurecimia and gout with metabolic derangement

    Treating Asymptomatic Hyperuricemia Could Lower Risk of Developing Chronic Conditions

    August 12, 2016

    When uric acid becomes elevated in the human body, a variety of problems can develop, most notably gout—a painful, inflammatory arthritis caused by uric acid crystal deposition in joints. Chronically elevated uric acid can also lead to painful kidney stones. The majority of patients found to have hyperuricemia, however, never go on to develop gout…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences